Modified HER-2 Tumor Antigens for Vaccination in Cancer

用于癌症疫苗接种的修饰 HER-2 肿瘤抗原

• 批准号: 7288356
• 负责人: Mark J Mamula
• 金额: $ 57.48万
• 依托单位: L2 DIAGNOSTICS, LLC
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-03-01 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7288356
• 关键词: Adjuvant; Affect; Animals; Antibodies; Antibody Formation; Antibody Specificity; Applications Grants; Autoantigens; Autoimmunity; Binding; Biological; Blocking Antibodies; Breast Cancer Cell; Breast Cancer Model; Breast Cancer Treatment; Cells; Chronic; Clinical Trials; Complement; Cultured Cells; Cytolysis; Data; Development; Disease regression; ERBB2 gene; Epitopes; Evolution; Extracellular Domain; Goals; Growth; Human; Immune Tolerance; Immune response; Immunity; Immunization; Immunoassay; Immunohistochemistry; Immunotherapy; In Vitro; Individual; Infiltration; Life; Link; Malignant Neoplasms; Mediating; Molecular; Monoclonal Antibodies; Mus; Mutate; Patients; Peptides; Phase; Phase I Clinical Trials; Phase II Clinical Trials; Property; Protein Overexpression; Proteins; Protocols documentation; Research; Roche brand of trastuzumab; Secondary Immunization; Site; Solid; Standards of Weights and Measures; T-Lymphocyte; Therapeutic; Tissues; Toll-like receptors; Trastuzumab; Tumor Antigens; Tumor Immunity; Vaccination; Vaccines; Weight; Work; aluminum sulfate; antibody-dependent cell cytotoxicity; base; cell growth; clinical efficacy; concept; dosage; human tissue; improved; in vivo; inhibiting antibody; killings; malignant breast neoplasm; neoplastic cell; novel; response; size; success; tissue culture; tumor; tumor growth; vaccination strategy

DESCRIPTION (provided by applicant): Breast cancer remains 1 of the most insidious and difficult to treat human malignancies, affecting thousands of individuals each year. Our proposed studies are aimed at developing a novel tumor immunotherapy by using cryptic peptides of Her-2 protein and modified Her-2 peptides, both of which break immune tolerance to "self " tumor antigens expressed on breast cancer cells. In general, most tumor antigens have been characterized as normal, non-mutated self peptides, linking the concepts of autoimmunity with the development of tumor immunity. Our phase I studies have demonstrated the ability of peptide vaccination to elicit anti-Her-2 antibodies that resemble Herceptin, a monoclonal antibody currently approved for immunotherapy of human breast cancer. Similar to Her-2 binding by Herceptin, antibodies induced by peptide vaccination bind native Her-2 protein on living tumor cells and in solid phase immunoassays, as well as denatured Her-2 protein and peptides therein. We have demonstrated that immunization with Her-2 peptides elicits antibodies that inhibit tumor cell growth in vitro and in vivo. The goal of the Phase II study is to develop enhanced anti-Her-2 tumor immunity with a select group of Her-2 peptides in combination with adjuvants approved for human use, alum and novel TLR-based adjuvants. At present, antibody-mediated treatment of breast cancer requires prolonged administration of the therapeutic. This work will attempt to establish vaccine- based long term immunity with antibody specificities and biologic efficacy comparable to Herceptin therapy. The overall objective of this research is to develop peptide-based vaccination strategies to mimic the anti-tumor properties of Herceptin, an antibody with proven clinical efficacy in patients with breast cancer.

描述（由申请人提供）：乳腺癌仍然是最隐蔽和最难治疗的人类恶性肿瘤之一，每年影响成千上万的人。我们的研究旨在开发一种新的肿瘤免疫疗法，利用Her-2蛋白的隐肽和修饰的Her-2肽，这两种肽都能打破对乳腺癌细胞上表达的“自我”肿瘤抗原的免疫耐受。一般来说，大多数肿瘤抗原的特征是正常的，非突变的自身肽，将自身免疫的概念与肿瘤免疫的发展联系起来。我们的I期研究已经证明，肽疫苗接种能够引发类似赫赛汀的抗her -2抗体，赫赛汀是一种目前被批准用于人类乳腺癌免疫治疗的单克隆抗体。与Herceptin结合Her-2类似，肽疫苗诱导的抗体将天然Her-2蛋白结合在活肿瘤细胞和固相免疫测定中，以及变性Her-2蛋白和其中的肽。我们已经证明，Her-2肽免疫可在体外和体内诱导抑制肿瘤细胞生长的抗体。II期研究的目标是通过筛选Her-2多肽与经批准的人用佐剂、明矾和新型tlr佐剂联合，开发增强的抗Her-2肿瘤免疫。目前，抗体介导的乳腺癌治疗需要延长治疗时间。这项工作将试图建立基于疫苗的长期免疫，具有抗体特异性和可与赫赛汀治疗相媲美的生物功效。这项研究的总体目标是开发基于肽的疫苗接种策略，以模仿赫赛汀的抗肿瘤特性，赫赛汀是一种已被证实对乳腺癌患者有临床疗效的抗体。